Promoter methylation of BRCA1 is associated with estrogen, progesterone and human epidermal growth factor receptor‑negative tumors and the prognosis of breast cancer: A meta-analysis

Guo,Taiyan; Ren,Yongyong; Wang,Boyuan; Huang,Yingze; Jia,Shuting; Tang,Wenru; Luo,Ying

doi:10.3892/mco.2015.620

Promoter methylation of BRCA1 is associated with estrogen, progesterone and human epidermal growth factor receptor‑negative tumors and the prognosis of breast cancer: A meta-analysis

Authors:
- Taiyan Guo
- Yongyong Ren
- Boyuan Wang
- Yingze Huang
- Shuting Jia
- Wenru Tang
- Ying Luo
View Affiliations

Affiliations: Laboratory of Molecular Genetics of Aging and Tumor, Faculty of Medicine, Kunming University of Science and Technology, Kunming, Yunnan 650500, P.R. China, Laboratory of Medical Genetics and Pharmacogenomics, Faculty of Medicine, Kunming University of Science and Technology, Kunming, Yunnan 650500, P.R. China
Published online on: August 11, 2015 https://doi.org/10.3892/mco.2015.620
Pages: 1353-1360

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Aberrant methylation of the breast cancer susceptibility gene 1 (BRCA1) promoter is a mechanism for its functional inactivation. It may potentially be used as a prognostic marker in studies for patients with breast cancer and plays an important role in tumorigenesis. Numerous studies have suggested that the methylation of the BRCA1 promoter is associated with the prognosis of breast cancer. However, the prognosis of BRCA1 promoter methylation in breast cancer patients of different ethnicities remains ambiguous. The present meta‑analysis was performed to adjust and augment a previously published study, which estimated the correlations between promoter methylation of BRCA1 and the clinical outcomes of breast cancer patients. These results indicated that BRCA1 methylation was significantly correlated with a poor prognosis of breast cancer, particularly for Asian patients, but the correlation was over‑estimated in the previous study. The combined hazard ratios (HRs) in the present study were 1.76 (1.15‑2.68) and 1.97 (1.12‑3.44) for univariate and multivariate analysis of overall survival, which were different from 2.02 (1.35‑3.03) and 1.38 (1.04‑1.84) in the previous study. For studies of disease‑free survival, the univariate and multivariate analyses also have different pooled HRs: 2.89 (1.73‑4.83) and 3.92 (1.49‑10.32) in the previously published study and 1.28 (0.68‑2.43) and 1.64 (0.64‑4.19) in the present study. In addition, the BRCA1 promoter regions used to detect the hypermethylation were different. All the studies using the Baldwin's primer reported that breast cancer patients with BRCA1 promoter methylation had a better prognosis. There were also correlations between BRCA1 promoter methylation and receptor‑negativity of the estrogen receptors, progesterone receptor, human epidermal growth factor receptor 2 and a triple‑negative status. Patients with the estrogen, progesterone and epidermal growth factor‑related receptor‑negative status were more likely to be negative for the BRCA1 protein.

View Figures

View References

1	Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 59:225–249. 2009. View Article : Google Scholar : PubMed/NCBI
2	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
3	Russo J, Yang X, Hu YF, Bove BA, Huang Y, Silva ID, Tahin Q, Wu Y, Higgy N, Zekri A, et al: Biological and molecular basis of human breast cancer. Front Biosci. 3:D944–D960. 1998.PubMed/NCBI
4	Miki Y, Swensen J, ShattuckEidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W, et al: A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 266:66–71. 1994. View Article : Google Scholar : PubMed/NCBI
5	Friedenson B: The BRCA1/2 pathway prevents hematologic cancers in addition to breast and ovarian cancers. BMC Cancer. 7:1522007. View Article : Google Scholar : PubMed/NCBI
6	Ralhan R, Kaur J, Kreienberg R and Wiesmüller L: Links between DNA double strand break repair and breast cancer: Accumulating evidence from both familial and nonfamilial cases. Cancer Lett. 248:1–17. 2007. View Article : Google Scholar : PubMed/NCBI
7	Hall JM, Lee MK, Newman B, Morrow JE, Anderson LA, Huey B and King MC: Linkage of early-onset familial breast cancer to chromosome 17q21. Science. 250:1684–1689. 1990. View Article : Google Scholar : PubMed/NCBI
8	Birgisdottir V, Stefansson OA, Bodvarsdottir SK, Hilmarsdottir H, Jonasson JG and Eyfjord JE: Epigenetic silencing and deletion of the BRCA1 gene in sporadic breast cancer. Breast Cancer Res. 8:R382006. View Article : Google Scholar : PubMed/NCBI
9	Wu L, Wang F, Xu R, Zhang S, Peng X, Feng Y, Wang J and Lu C: Promoter methylation of BRCA1 in the prognosis of breast cancer: A meta-analysis. Breast Cancer Res Treat. 142:619–627. 2013. View Article : Google Scholar : PubMed/NCBI
10	DahlmanWright K, Cavailles V, Fuqua SA, Jordan VC, Katzenellenbogen JA, Korach KS, Maggi A, Muramatsu M, Parker MG and Gustafsson JA: International Union of Pharmacology. LXIV. Estrogen receptors. Pharmacol Rev. 58:773–781. 2006. View Article : Google Scholar : PubMed/NCBI
11	Mitri Z, Constantine T and O'Regan R: The HER2 receptor in breast cancer: Pathophysiology, clinical use, and new advances in therapy. Chemother Res Pract. 2012:7431932012.PubMed/NCBI
12	Bosch A, Eroles P, Zaragoza R, Viña JR and Lluch A: Triple-negative breast cancer: Molecular features, pathogenesis, treatment and current lines of research. Cancer Treat Rev. 36:206–215. 2010. View Article : Google Scholar : PubMed/NCBI
13	Fleiss JL: The statistical basis of meta-analysis. Stat Methods Med Res. 2:121–145. 1993. View Article : Google Scholar : PubMed/NCBI
14	Tierney JF, Stewart LA, Ghersi D, Burdett S and Sydes MR: Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 8:162007. View Article : Google Scholar : PubMed/NCBI
15	DerSimonian R: Meta-analysis in the design and monitoring of clinical trials. Stat Med. 15:1237–1252. 1996. View Article : Google Scholar : PubMed/NCBI
16	Higgins JP, Thompson SG, Deeks JJ and Altman DG: Measuring inconsistency in meta-analyses. BMJ. 327:557–560. 2003. View Article : Google Scholar : PubMed/NCBI
17	Bax L, Ikeda N, Fukui N, Yaju Y, Tsuruta H and Moons KG: More than numbers: The power of graphs in meta-analysis. Am J Epidemiol. 169:249–255. 2009. View Article : Google Scholar : PubMed/NCBI
18	Egger M, Davey Smith G, Schneider M and Minder C: Bias in meta-analysis detected by a simple, graphical test. BMJ. 315:629–634. 1997. View Article : Google Scholar : PubMed/NCBI
19	Lau J, Ioannidis JP and Schmid CH: Quantitative synthesis in systematic reviews. Ann Intern Med. 127:820–826. 1997. View Article : Google Scholar : PubMed/NCBI
20	Sharma P, Stecklein SR, Kimler BF, Sethi G, Petroff BK, Phillips TA, Tawfik OW, Godwin AK and Jensen RA: The prognostic value of BRCA1 promoter methylation in early stage triple negative breast cancer. J Cancer Ther Res. 3:1–11. 2014. View Article : Google Scholar : PubMed/NCBI
21	Ignatov T, Poehlmann A, Ignatov A, Schinlauer A, Costa SD, Roessner A, Kalinski T and Bischoff J: BRCA1 promoter methylation is a marker of better response to anthracycline-based therapy in sporadic TNBC. Breast Cancer Res Treat. 141:205–212. 2013. View Article : Google Scholar : PubMed/NCBI
22	Krasteva ME, Bozhanov SS, Antov GG, Gospodinova ZI and Angelov SG: Breast cancer patients with hypermethylation in the promoter of BRCA1 gene exhibit favorable clinical status. Neoplasma. 59:85–91. 2012. View Article : Google Scholar : PubMed/NCBI
23	Xu X, Gammon MD, Zhang Y, Bestor TH, Zeisel SH, Wetmur JG, Wallenstein S, Bradshaw PT, Garbowski G, Teitelbaum SL, et al: BRCA1 promoter methylation is associated with increased mortality among women with breast cancer. Breast Cancer Res Treat. 115:397–404. 2009. View Article : Google Scholar : PubMed/NCBI
24	Xu Y, Diao L, Chen Y, Liu Y, Wang C, Ouyang T, Li J, Wang T, Fan Z, Fan T, et al: Promoter methylation of BRCA1 in triple-negative breast cancer predicts sensitivity to adjuvant chemotherapy. Ann Oncol. 24:1498–1505. 2013. View Article : Google Scholar : PubMed/NCBI
25	Hsu NC, Huang YF, Yokoyama KK, Chu PY, Chen FM and Hou MF: Methylation of BRCA1 promoter region is associated with unfavorable prognosis in women with early-stage breast cancer. PLoS One. 8:e562562013. View Article : Google Scholar : PubMed/NCBI
26	Sharma G, Mirza S, Yang YH, Parshad R, Hazrah P, Datta Gupta S and Ralhan R: Prognostic relevance of promoter hypermethylation of multiple genes in breast cancer patients. Cell Oncol. 31:487–500. 2009.PubMed/NCBI
27	Chen Y, Zhou J, Xu Y, Li Z, Wen X, Yao L, Xie Y and Deng D: BRCA1 promoter methylation associated with poor survival in Chinese patients with sporadic breast cancer. Cancer Sci. 100:1663–1667. 2009. View Article : Google Scholar : PubMed/NCBI
28	Jing F, Jun L, Yong Z, Wang Y, Fei X, Zhang J and Hu L: Multigene methylation in serum of sporadic Chinese female breast cancer patients as a prognostic biomarker. Oncology. 75:60–66. 2008. View Article : Google Scholar : PubMed/NCBI
29	KarrayChouayekh S, Trifa F, Khabir A, Boujelbane N, SellamiBoudawara T, et al: Clinical significance of epigenetic inactivation of hMLH1 and BRCA1 in Tunisian patients with invasive breast carcinoma. J Biomed Biotechnol. 2009:3691292009.PubMed/NCBI
30	Baldwin RL, Nemeth E, Tran H, Shvartsman H, Cass I, et al: BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study. Cancer Res. 60:5329–5333. 2000.PubMed/NCBI
31	Esteller M, Silva JM, Dominguez G, Bonilla F, MatiasGuiu X, et al: Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst. 92:564–569. 2000. View Article : Google Scholar : PubMed/NCBI
32	Patsopoulos NA, Evangelou E and Ioannidis JP: Sensitivity of between-study heterogeneity in meta-analysis: proposed metrics and empirical evaluation. Int J Epidemiol. 37:1148–1157. 2008. View Article : Google Scholar : PubMed/NCBI
33	Sharma G, Mirza S, Parshad R, et al: Clinical significance of promoter hypermethylation of DNA repair genes in tumor and serum DNA in invasive ductal breast carcinoma patients. Life Sci. 87:83–91. 2010. View Article : Google Scholar : PubMed/NCBI